OptiMedica Corporation is a Silicon Valley-based global ophthalmic device company dedicated to developing performance-driven technologies that improve patient outcomes. The company was founded in 2004 with the vision of bringing innovative new technologies to ophthalmologists and transforming existing standards of care.
Since its founding, OptiMedica has been developing a reproducible, noninvasive technique to replace the inconsistent manual steps in cataract surgery with femtosecond laser technology. The system has been designed to deliver new levels of precision, control, performance, and efficacy to cataract surgeons and their patients. OptiMedica has completed clinical trials of its Catalys™ Precision Laser System, with very promising results reported across these measures.
OptiMedica has a legacy of delivering transformational change in ophthalmology. The company’s initial commercial effort was in retina, where its research and development team sought to rethink panretinal photocoagulation (PRP) to dramatically improve the precision, efficiency and comfort of the procedure. OptiMedica licensed pattern scanning laser technology from Stanford University, and its PASCAL® (PAttern SCAn Laser) Method of photocoagulation transformed the retinal photocoagulation market.
In less than four years after the launch of the first PASCAL photocoagulator in 2006, the company shipped more than 600 PASCAL units in more than 40 markets around the world, and these systems were used to treat more than 750,000 patients and deliver more than 30 million patterns. This success drew the attention of global ophthalmic company Topcon Corp., which added PASCAL technology to its product portfolio in 2008 and ultimately chose to acquire OptiMedica’s retina and glaucoma technology in August 2010. The transaction, which represented the largest acquisition in the history of Topcon Corp.’s medical device business, provided Topcon Corp. with a rich therapeutic product portfolio and a pipeline of retina innovation, while delivering to OptiMedica significant funding for its breakthrough laser cataract surgery effort.